Laboratory tests in primary care · by Dr Solange Déplanque and Dr Michaël Rochoy

Cholestasis in adults (raised ALP and GGT)

Gastroenterology and hepatology · Abnormal laboratory result · updated 2026-10-31

BioMG follows French guidelines. Adapt it to the guidelines and the tests available where you practise.

Frequency: In primary care in Scotland (Tayside, 1989-2003), 21.7% of patients who had first-line liver function tests had at least one abnormal test (all profiles combined, not cholestasis alone); no frequency data specific to cholestasis (raised ALP + GGT) were found [1].

Fever, chills, jaundice, dilated bile ducts: emergency

Detailed explanation and international comparison (in French): read it in English (machine translation)

Cholestasis without emergency signs: ultrasound and first tests

Fasting sample.

Fasting laboratory tests

Detailed explanation and international comparison (in French): read it in English (machine translation)

Intrahepatic cholestasis, negative antimitochondrial antibodies

Laboratory tests

Detailed explanation and international comparison (in French): read it in English (machine translation)

Sources (12)
  1. Donnan PT, McLernon D, Dillon JF, et al. Development of a decision support tool for primary care management of patients with abnormal liver function tests without clinically apparent liver disease: a record-linkage population cohort study and decision analysis (ALFIE). Health Technol Assess. 2009;13(25):iii-iv, ix-xi, 1-134.
  2. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol. 2009;51(2):237-67.
  3. Maffei M, Hadengue A. Cholestase de l'adulte. 1. Démarche diagnostique. Rev Med Suisse. 2006;2(77):1960-4.
  4. Newsome PN, Cramb R, Davison SM, et al. Guidelines on the management of abnormal liver blood tests (British Society of Gastroenterology). Gut. 2018;67(1):6-19.
  5. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017;67(1):145-172.
  6. Kwo PY, Cohen SM, Lim JK. ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries. Am J Gastroenterol. 2017;112(1):18-35.
  7. Association française pour l'étude du foie (AFEF). Recommandations pour le diagnostic et le suivi non-invasif des maladies chroniques du foie. Juillet 2020. Chapitre 6 : cholangite biliaire primitive (C. Corpechot) ; chapitre 7 : cholangite sclérosante primitive (O. Chazouillères).
  8. Hirschfield GM, Dyson JK, Alexander GJM, et al. The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines. Gut. 2018;67(9):1568-1594.
  9. Chapman MH, Thorburn D, Hirschfield GM, et al. British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis. Gut. 2019;68(8):1356-1378.
  10. Lindor KD, Kowdley KV, Harrison ME. ACG Clinical Guideline: Primary Sclerosing Cholangitis. Am J Gastroenterol. 2015;110(5):646-659.
  11. ANSM, Base de données publique des médicaments. Résumé des caractéristiques du produit FURADANTINE 50 mg (nitrofurantoïne), gélule, rubrique 4.8.
  12. ANSM, Base de données publique des médicaments. Résumé des caractéristiques du produit CAPTOPRIL EG 25 mg, comprimé (captopril), rubrique 4.8.